Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00954447. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of Linagliptin (5 mg), Administered Orally Once Daily for at Least 52 Weeks in Type 2 Diabetic Patients in Combination With Basal Insulin Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
Study identification
- NCT ID
- NCT00954447
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,263 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2009 (Type not available)
- Primary completion
- Sep 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 30, 2013
Started 2009
United States locations
- U.S. sites
- 47
- U.S. states
- 21
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1218.36.01043 Boehringer Ingelheim Investigational Site | Escondido | California | — | — |
| 1218.36.01051 Boehringer Ingelheim Investigational Site | Escondido | California | — | — |
| 1218.36.01065 Boehringer Ingelheim Investigational Site | Fresno | California | — | — |
| 1218.36.01021 Boehringer Ingelheim Investigational Site | Greenbrae | California | — | — |
| 1218.36.01013 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1218.36.01048 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1218.36.01058 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1218.36.01008 Boehringer Ingelheim Investigational Site | Santa Ana | California | — | — |
| 1218.36.01056 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 1218.36.01054 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1218.36.01035 Boehringer Ingelheim Investigational Site | Inverness | Florida | — | — |
| 1218.36.01010 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1218.36.01042 Boehringer Ingelheim Investigational Site | New Port Richey | Florida | — | — |
| 1218.36.01063 Boehringer Ingelheim Investigational Site | Pembroke Pines | Florida | — | — |
| 1218.36.01037 Boehringer Ingelheim Investigational Site | Ponte Vedra | Florida | — | — |
| 1218.36.01032 Boehringer Ingelheim Investigational Site | Saint Cloud | Florida | — | — |
| 1218.36.01049 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 1218.36.01036 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1218.36.01047 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1218.36.01009 Boehringer Ingelheim Investigational Site | Roswell | Georgia | — | — |
| 1218.36.01055 Boehringer Ingelheim Investigational Site | Honolulu | Hawaii | — | — |
| 1218.36.01014 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1218.36.01011 Boehringer Ingelheim Investigational Site | Paducah | Kentucky | — | — |
| 1218.36.01034 Boehringer Ingelheim Investigational Site | City of Saint Peters | Missouri | — | — |
| 1218.36.01040 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1218.36.01029 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1218.36.01018 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1218.36.01053 Boehringer Ingelheim Investigational Site | New Hartford | New York | — | — |
| 1218.36.01006 Boehringer Ingelheim Investigational Site | Burlington | North Carolina | — | — |
| 1218.36.01025 Boehringer Ingelheim Investigational Site | Hickory | North Carolina | — | — |
| 1218.36.01005 Boehringer Ingelheim Investigational Site | Statesville | North Carolina | — | — |
| 1218.36.01015 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1218.36.01039 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 1218.36.01019 Boehringer Ingelheim Investigational Site | Altoona | Pennsylvania | — | — |
| 1218.36.01012 Boehringer Ingelheim Investigational Site | Norristown | Pennsylvania | — | — |
| 1218.36.01004 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1218.36.01020 Boehringer Ingelheim Investigational Site | Simpsonville | South Carolina | — | — |
| 1218.36.01003 Boehringer Ingelheim Investigational Site | Kingsport | Tennessee | — | — |
| 1218.36.01038 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1218.36.01016 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1218.36.01026 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 1218.36.01041 Boehringer Ingelheim Investigational Site | Bennington | Vermont | — | — |
| 1218.36.01064 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1218.36.01024 Boehringer Ingelheim Investigational Site | Lakewood | Washington | — | — |
| 1218.36.01007 Boehringer Ingelheim Investigational Site | Renton | Washington | — | — |
| 1218.36.01027 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1218.36.01062 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 122 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00954447, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 30, 2013 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00954447 live on ClinicalTrials.gov.